Oxford Biomedica plc (LON:OXB)
London · Delayed Price · Currency is GBP · Price in GBX 571.00
-13.00 (-2.23%)
Jul 24, 2026, 5:12 PM GMT
Oxford Biomedica Financials Overview
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 168.74 | 168.74 | 128.8 | 89.54 | 139.99 | 142.8 |
Revenue Growth | 11.59% | 31.01% | 43.84% | -36.04% | -1.97% | 62.77% |
Gross Profit Gross Profit Growth | 65.98 | 65.98 | 53.02 | 39.73 | 69.18 | 82.64 |
Operating Income Operating Income Growth | -22.48 | -22.48 | -39.38 | -184.17 | -30.22 | 20.77 |
Net Income Net Income Growth | -30.13 | -30.13 | -43.19 | -157.49 | -39.16 | 19.01 |
Earnings Per Share EPS Growth | -0.27 | -0.27 | -0.42 | -1.63 | -0.41 | 0.22 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Manufacturing Services Manufacturing Services Growth | 81.06 | 81.06 | 68.35 | 51.05 |
Licences, Milestones and Royalties Licences, Milestones and Royalties Growth | 5.27 | 5.27 | 7.33 | 6.68 |
Development Services Development Services Growth | 60.11 | 60.11 | 47.27 | 31.81 |
Procurement Services Procurement Services Growth | 22.3 | 22.3 | 5.85 | - |
Total Total Growth | 168.74 | 168.74 | 128.8 | 89.54 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 96.88 | 96.88 | 60.65 | 103.72 | 141.29 | 108.94 |
Total Debt Total Debt Growth | 148.13 | 148.13 | 108.76 | 111.46 | 114.28 | 9.34 |
Net Cash (Debt) Net Cash Growth | -51.24 | -51.24 | -48.11 | -7.74 | 27 | 99.6 |
Net Cash Growth | - | - | - | - | -72.89% | 202.76% |
Net Cash Per Share Net Cash Per Share Growth | -0.46 | -0.46 | -0.47 | -0.08 | 0.28 | 1.19 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 0.51 | 0.51 | -50.67 | -28.52 | -12.62 | 25.46 |
Capital Expenditures CapEx Growth | -4.76 | -4.76 | -7.5 | -9.83 | -16.3 | -9.46 |
Free Cash Flow Free Cash Flow Growth | -4.25 | -4.25 | -58.16 | -38.35 | -28.91 | 15.99 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 39.10% | 39.10% | 41.17% | 44.37% | 49.42% | 57.87% |
Operating Margin | -13.32% | -13.32% | -30.57% | -205.69% | -21.59% | 14.54% |
Pretax Margin | -18.93% | -18.93% | -36.70% | -210.55% | -32.84% | 13.92% |
Profit Margin | -18.16% | -18.16% | -37.74% | -205.68% | -32.26% | 13.31% |
FCF Margin | -2.52% | -2.52% | -45.16% | -42.83% | -20.65% | 11.20% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | - | 55.41 |
Forward PE | - | 113.10 | 113.10 | 113.10 | 113.10 | 60.29 |
P/FCF Ratio | - | - | - | - | - | 64.20 |
PS Ratio | 4.10 | 4.41 | 3.37 | 2.37 | 3.00 | 7.19 |